{
    "clinical_study": {
        "@rank": "114446", 
        "arm_group": [
            {
                "arm_group_label": "dHACM", 
                "arm_group_type": "Experimental", 
                "description": "Total knee arthroplasty, per the usual practice of the physician with application of dHACM between the underlying fascia and the overlying skin layers to reduce scar formation"
            }, 
            {
                "arm_group_label": "Control", 
                "arm_group_type": "Other", 
                "description": "Total knee arthroplasty, per the usual practice of the physician without application of dHACM."
            }
        ], 
        "brief_summary": {
            "textblock": "The overall objective of this study is to evaluate the effectiveness of dHACM in reducing\n      scar tissue formation in total knee replacement patients."
        }, 
        "brief_title": "Amniotic Membrane in Total Knee Replacements to Reduce Scarring", 
        "condition": "Scarring", 
        "condition_browse": {
            "mesh_term": "Cicatrix"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Are adults ages 18 or older.\n\n          2. Are diagnosed with advanced osteoarthritis as determined by clinical exam and\n             necessitate total knee replacement.\n\n          3. Have a willingness to comply with follow-up examination.\n\n          4. Have ability to give full written consent.\n\n        Exclusion Criteria:\n\n          1. Has had a previous total or partial joint replacement performed at the same site\n\n          2. Has a planned bilateral procedure at this time. Bilateral patients can be enrolled if\n             the procedures are staged.\n\n          3. Has signs or symptoms of any other disease which could result in allograft failure,\n             or has experienced allograft failure in the past.\n\n          4. Has used any investigational drug(s) or therapeutic device(s) within 30 days\n             preceding screening.\n\n          5. Is pregnant or may become pregnant during the study.\n\n          6. Is a prisoner.\n\n          7. Has any condition(s) which seriously compromises the subject's ability to participate\n             in this study, or has a known history of poor adherence with medical treatment.\n\n          8. Is currently taking medications which could affect allograft incorporation\n             (supervising physician's discretion).\n\n          9. Is confined to bed or a wheelchair.\n\n         10. Has clinical signs and symptoms of local infection at the site.\n\n         11. Has autoimmune disease or a known history of having Acquired Immunodeficiency\n             Syndrome (AIDS) or HIV.\n\n         12. Has current diagnosis of cancer at the site.\n\n         13. Has had prior radiation therapy treatment at the site.\n\n         14. Is currently taking anticoagulant therapy.\n\n         15. Is unable to sign or understand informed consent.\n\n         16. Has a history of drug or alcohol abuse within last 12 months.\n\n         17. Is allergic to Aminoglycoside antibiotics (such as gentamicin and/or streptomycin)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "52", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02088567", 
            "org_study_id": "AFTKR001"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "dHACM", 
                    "Control"
                ], 
                "description": "Total knee arthroplasty, per the usual practice of the physician.", 
                "intervention_name": "Total Knee Arthroplasty", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "dHACM", 
                "description": "Application of dHACM at end of procedure before closing wound between the underlying fascia and the overlying skin layers to reduce scar formation", 
                "intervention_name": "Application of dHACM", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 13, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Decatur", 
                    "country": "United States", 
                    "state": "Georgia", 
                    "zip": "30033"
                }, 
                "name": "Georgia Knee and Sports Medicine"
            }, 
            "investigator": {
                "last_name": "Maurice Jove, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Prospective Randomized Clinical Trial Using Dehydrated Human Amnion/Chorion Membrane (dHACM) in Total Knee Replacement Patients to Reduce Post-operative Scarring.", 
        "other_outcome": {
            "description": "Western Ontario and McMaster Universities Arthritis Index (WOMAC) and Short Form 36 (SF-36) are measures of patient health status and quality of life.", 
            "measure": "Increased Quality of Life as assessed by WOMAC and SF-36", 
            "safety_issue": "No", 
            "time_frame": "6 weeks"
        }, 
        "overall_contact": {
            "last_name": "Maurice Jove, MD", 
            "phone": "(404) 296-5005"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Increased range of motion between both groups as measured by goniometer", 
            "safety_issue": "No", 
            "time_frame": "6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02088567"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Incidence of need for manual manipulation of affected knee", 
            "safety_issue": "No", 
            "time_frame": "6 weeks"
        }, 
        "source": "MiMedx Group, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "MiMedx Group, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}